• Explore /
  • Poster
  • / Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Abstract Poster

Authors

Ewald Woell

Ewald Woell

St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria

Ewald Woell , Josef Thaler , Felix Keil , Wolfgang Eisterer , Michael A. Fridrik , Birgit Gruenberger , Michael Hejna , Franz Romeder , Richard Greil

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal, Gastric, or Small Bowel

Clinical Trial Registration Number

2008-006128-79

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4074)

DOI

10.1200/jco.2012.30.15_suppl.4074

Abstract #

4074

Poster Bd #

45A

Abstract Disclosures

Similar Posters

First Author: Patrick M Boland

First Author: Marc Van Den Eynde

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

First Author: Masahiro Yanagi

First Author: Hyung-Don Kim